Next year is shaping up to be slightly better for global pharma growth. But once again, it’s emerging markets leading the charge. According to IMS Health’s annual forecast, double-digit expansion in developing countries next year will make up for less-exciting growth in the U.S. and Europe.
Continue reading ‘China to Fuel Bigger Pharma Growth in 2011′
With all the buzz about Sanofi’s new Covance deal and its ongoing struggle to gain control of Genzyme, it was easy to overlook CEO Chris Viehbacher’s pipeline review for the Big Pharma company. Viehbacher has been engaged in a head-to-toe revamp of R&D from his first day at the helm. Late last week he pronounced the effort as still very much a work in progress. But he laid bare some key strategies that will drive partnerships and outsourcing plans for years to come–regardless of what happens with Genzyme.
Continue reading ‘Big Pharma’s Finding New Ways to Cut Costs and Speed Up Trials’
President Barack Obama said politicians who want to repeal this year’s health-care overhaul should have to explain to people who need insurance that they won’t be able to buy it. “I want them to look you in the eye and say sorry,” he said, “you can’t buy health insurance.” “I don’t think that’s what this country stands for,” the president said at a backyard gathering in Falls Church, Virginia.
Continue reading ‘Obama Steps Up Defense of Health-Care Overhaul Law’
In its report on Suzhou Natong Bionanotechnology’s microneedle technology, the Wall Street Journal hits on an interesting problem in the drug-delivery world: Is it a device or a drug? Since often the delivery technology often enters the body along with the drug, the old categories often do not work.
Brian Orelli of The Motley Fool highlights four drugs–AstraZeneca’s Brilinta, Questcor’s Acthar Gel, Savient’s Krystexxa and Novartis’ Gilenia–that could gain FDA approval this month despite some previous difficulties. However, given recent troubles with other approved drugs, the FDA’s cautious nature could cause issues for some of the drugmakers.
Continue reading ‘Four Drugs Look to Pass FDA Muster this Month’
Here’s a tip for sales reps barred from certain physicians’ offices–catch them at a meeting instead. As the number of doctors who readily accept calls from pharma reps continues to shrink, sales folks are looking for work-arounds. And one that seems to work is chatting with docs at industry meetings, a new survey shows.
El Camino Hospital in Los Gatos and Mountain View, Calif. said it plans to lay off 140 employees by the end of October in an attempt to save money. The hospital sent out warning notices to 195 employees, reports San Jose Mercury News. There are approximately 460 employees in Los Gatos and 2,600 in Mountain View.
Continue reading ‘Hospital Cuts Staff, Hires Robots to Save Costs’
Surgeons tweeted updates during a recent double hand transplant at Jewish Hospital Hand Care Center in Louisville. While the operation would be only the third double hand transplant in the U.S., it’s probably the first accompanied by live tweeting.
Continue reading ‘Surgeons use Twitter during Double-Hand Transplant’
A team headed by researchers from the Salk Institute for Biological Studies and the Sanford-Burnham Medical Research Institute has been awarded a $21 million grant to ascertain how the immune system reacts immediately after it is exposed to the AIDS virus. The project will bring together the expertise of 13 research groups at seven institutions to uncover the cellular protein machinery that represents the first line of defense against HIV.
More drugs are hitting the recall list these days. As CNN Money reports, the number of recalls hit 1,742 last year–that’s an increase of 309 percent over 2008. “We’ve seen a trend where the last four years are among the top five for the most number of drug recalls since we began tallying recalls in 1988,” says Bowman Cox, managing editor of the Gold Sheet, a trade pub that analyzes FDA data. “That’s a meaningful development.”
You are currently browsing the weblog archives for the Research Reports category.
Biotech Trading Signals Pharma News Biotech News